GSK's Role in FDA Effort to Approve Therapy for Autism-Related Condition
The CEO of GSK, Emma Walmsley, stated that the company has had a minimal role in the FDA's effort to approve a long-shelved drug for a condition associated with autism.
"We have no commercial interest, we have no scientific research, and we're not pursuing it. So it's just the administration at this stage."
The FDA requested that GSK update the prescribing information for its decades-old therapy leucovorin, which the CEO described as "an administrative request".
GSK is not actively pursuing the approval of leucovorin for the treatment of the autism-related condition.
Author's summary: GSK plays down its role in FDA effort.
- Company: GSK
- Drug: leucovorin
- Condition: autism-related
More News
- Vanessa Kite | Founder of Rakau Ora Charitable Trust – Mental Wellness
- Republican justices appear poised to destroy what’s left of the Voting Rights Act
- ONLY ON 13: Relatives of family killed by drunk driver call for action
- Nanaimo car dealership adopts sunny business outlook with name change
- New details of deadly Albany fire investigation may come later this week
- Oklahoma lawmakers examine hazards of abandoned marijuana facilities
- Brad Marchand pulls famous quote to get back at Paul Bissonnette
- UK's Starmer publishes evidence in collapsed China spy case
- Africa’s Best Energy Choice Is Geothermal
- Charlie Kirk: Courageous for His Faith